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Abstract
Concurrent hemolysis in patients with vitamin B12 deficiency is a well-recognized phenomenon and
has been attributed to intramedullary destruction of erythrocytes (ineffective erythropoiesis).
Recent studies revealed that homocysteine increased the risk of hemolysis in vitamin B12 deficiency
in vitro and there is a high frequency (30%) of vitamin B12 deficiency in asymptomatic patients with
homozygous methylene tetrahydrofolate reductase (MTHFR) C677T mutation, a known cause of
hyperhomocysteinemia. Here we report three patients with MTHFR mutations and vitamin B12
deficiency presenting with hemolytic anemia and severely elevated homocysteine levels. Patients
demonstrated complete resolution of hemolysis with simultaneous normalization of serum
homocysteine levels after vitamin B12 treatments. We reviewed pertinent literature, and
hypothesized that hemolytic anemia may be more prevalent in patients who have a coexisting
MTHFR gene mutation and vitamin B12 deficiency possibly related to severely elevated
homocysteine levels. The hemolysis in these cases occurred predominantly in peripheral blood
likely due to the combined effects of structurally defective erythrocytes and homocysteine-induced
endothelial damage with microangiopathy.
Background
Hematological consequences of vitamin B12 (cobalamin)
deficiency can be severe. It was estimated that 10% of the
patients had life threatening conditions such as sympto-
matic pancytopenia, "pseudo" thrombotic microangiopa-
thy, and hemolytic anemia [1]. Concurrent hemolysis in
patients with vitamin B12 deficiency has been attributed
to intramedullary destruction of red blood cells (ineffec-
tive erythropoiesis) [2]. However, studies revealed that
homocysteine accumulation due to vitamin B12 and
folate deficiency increased hemolysis in vitro [3,4]. A
recent study further demonstrated a high frequency
(30%) of vitamin B12 deficiency among 67 asymptomatic
patients with homozygous methylene tetrahydrofolate
reductase (MTHFR) C677T mutation, a cause of hyperho-
mocysteinemia [5]. In this case report, we identified three
cases of vitamin B12 deficiency and hemolytic anemia
associated with severe hyperhomocysteinemia and
MTHFR gene mutations. Resolution of hemolysis and
normalization of serum homocysteine levels were noted
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homocysteine levels may be an important contributor
leading to further hemolysis that is often seen in patients
with vitamin B12 deficiency.
Case presentation
Case 1
A 55 year-old white female with a history of hypothy-
roidism and pernicious anemia, had lost follow-up for 10
years. She presented with lethargy, confusion, exertional
dyspnea, difficulty with ambulation, and cold intoler-
ance. Abnormal physical findings included vitiligo, mod-
erate lower extremity edema and a mid-systolic click.
Laboratory findings revealed a hemoglobin (Hb) of 5.0 g/
dL (normal 12–16) with a mean corpuscular volume
(MCV) of 134 fL (normal 80–100); white cell count
(WBC) 3,100/mm3 (normal 3,500–11,000); platelet
123,000/mm3 (normal 140,000–450,000); and reticulo-
cyte count 6.3% (normal 0.5–2). Further study revealed
vitamin B12 level 167 pg/mL (normal 211–946), homo-
cysteine level 62.4 μmol/L (normal 5.0–13.9), methyl-
malonic acid level 13.53 μmol/L (normal 0 – 0.40),
haptoglobin levels < 6 mg/dL (normal 16–200) and lac-
tate dehydrogenase (LDH) 3152 U/L (normal 100–190).
Thyroid studies revealed a thyroid-stimulating hormone
(TSH) of 8.26 mlU/L (normal 0.37 – 4.42) with a thyroxin
level of 0.71 ng/dL (normal 0.75 – 2.00). Other chemistry
studies, including bilirubin levels, were normal. She was
heterozygous for methylene tetrahydrofolate reductase
(MTHFR) A1298C mutation. Peripheral smear was
remarkable for schistocytes and hypersegmented neu-
trophils (Figure 1).
Patient was transfused with 2 units of packed red blood
cells (RBC) and initiated on intramuscular vitamin B12
injections and daily levothyroxine supplement. Six weeks
later the Hb was 12.1 g/dL, MCV at 91.2 fL, homocysteine
level 14.6 μmol/L, TSH 4.27 and free T4 1.08 with
resolved WBC and platelet counts.
Case 2
A 58 year-old white male with a history of essential hyper-
tension and tobacco use was admitted with complaints of
progressively increasing fatigue over the past three to four
months. The patient denied hematochezia, hemoptysis,
or hematuria. However, the patient did report slight par-
esthesias in both soles, without significant alterations of
reflexes. Further history revealed a relatively recent change
in patient's dietary habits as he had adopted a strict vege-
tarian diet over the past fifteen months due to personal
experiences and convictions. His only medication was
rimipril.
Positive physical findings at the time of admission
included a slight conjunctival jaundice with pale skin and
weakness in the limbs. The patient was found to have a
macrocytic anemia with a slight increase in serum
bilirubin levels (2.1 mg/dL) in a screening blood test two
weeks prior to admission. Blood count on admission
showed a WBC 3,400/mm3, Hb 7.7 g/dL (MCV 115 fl),
and platelet 99,000/mm3. Serum vitamin B12 level was
100 pg/mL, whereas serum folate level, iron study, and
thyroid function tests were within normal range. Reticulo-
cyte count resulted 6% (normal range 2–6). Chemistry
results were remarkable for serum bilirubin 2.3 mg/dL
(1.9 mg/dL as unconjugated), elevated LDH (788 U/L)
and serum haptoglobin < 7 mg/dL. Plasma homocysteine
level was significantly increased at 88.8 μmol/L with an
elevated methylmalonic acid level at 12.1 μmol/L. Serum
creatinine, direct and indirect Coombs tests, and glucose-
6-phosphate dehydrogenase activity in red blood cells
were all normal. The patient resulted homozygous for
MTHFR C677T mutation. Peripheral blood smear and
marrow biopsy revealed a megaloblastic anemia with
megaloblastic erythroid hyperplasia with granulopoiesis
and megakaryocytosis (Figures 2 and 3).
During the one-week hospital stay, the patient was trans-
fused with 1 unit of packed RBC and started on intramus-
cular injections of cobalamin and oral supplementation
of folic acid. Meat was re-introduced in the patient's diet.
The patient underwent an esophago-gastroduodenoscopy
with gastric biopsy which exhibited evidence of atrophic
gastritis. Studies for antibodies to intrinsic factor and gas-
tric parietal cells were negative.
The patient was completely asymptomatic 4 months later
with the following blood test results: WBC 5,400/mm3,
Peripheral smear of case 1 demonstrated schistocytes and a hypers gment d neutrophilFigu  1
Peripheral smear of case 1 demonstrated schistocytes and a 
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serum vitamin B12 level 611 pg/mL, folate level 11.2 ng/
mL, and homocysteine level at 11.2 μmol/L. Bilirubin,
LDH and haptoglobin were all within the normal range.
Case 3
A 91 year-old white man with a history of atrial fibrilla-
tion, diabetes mellitus type 2 and atherosclerosis pre-
sented to the Emergency Department with complaints of
increasing fatigue, exertional dyspnea, progressively wors-
ening right upper quadrant pain and mild elevation of
serum bilirubin over the past 6 weeks. Mild elevation of
total bilirubin (ranging from 1.6 to 1.7 mg/dL) was
noticed in a screening blood test three months prior to
this presentation and no further work-up was initiated at
that time. The patient also had a mild macrocytic anemia
(hemoglobin at baseline 11.1 gm/dL with MCV 115 fL).
The patient denied hemopytsis, hematochezia, or hema-
turia. Medications included a glipizide, hydrochlorothi-
azide, furosemide, and warfarin.
Abnormal physical findings included pale skin, an irregu-
lar heart rhythm and right upper quadrant tenderness
with slight hepatomegaly, peripheral edema, varicosities
and symmetrical weakness in both lower extremities. Tho-
racic and abdominal computed tomography scans
revealed cardiomegaly and pleural effusion. Blood tests
revealed WBC 3,100/mm3, Hb 6.6 g/dL with MCV 146 fL
and platelet 97,000/mm3. The serum vitamin B12 level
was 162 pg/mL with a normal folate level (16.8 ng/mL)
and normal iron study. The homocysteine level was mark-
edly elevated at 129.7 μmol/L, and haptoglobin was < 7
mg/dL. Bone marrow aspirate revealed a cellular bone
marrow with 30% nucleated red blood cells with nuclear
to cytoplasmic dyssynchrony within the red cell series and
dyspoietic changes.
The patient was transfused with 2 units of packed RBC
and initiated on intramuscular cobalamin injections, and
was discharged in stable condition. Complete blood
counts 4 months later revealed WBC 4,400/mm3, Hb 11.3
g/dL with MCV 102 fL, and platelet 202,000/mm3. Eight
months later, vitamin B12 level was 586 pg/mL and his
CBC as follows: WBC 5,300, Hb 12.2, and platelet
206,000, which were all within normal ranges. His
bilirubin levels were normalized on the follow-up tests
after discharge from hospital. Unfortunately, follow up
homocysteine levels after cobalamin treatment were not
measured and the patient died three years later. However,
one of the patient's sons tested positive for homozygous
MTHFR C677T mutation.
Discussion
Concurrent hemolysis in patients with vitamin B12 defi-
ciency is a well-recognized phenomenon. While its mech-
anisms are not entirely understood, it is believed that the
hemolysis results from intramedullary destruction [2].
The patients reported here had ongoing hemolysis as evi-
denced by the undetectable levels of haptoglobin, with or
without elevated LDH and/or bilirubin as well as the pres-
ence of schistocytes in the peripheral blood smears (Fig-
ures 1, 2). While the third case did not have a follow-up
homocysteine level measured, we conjectured that the
high homocysteine levels preceding their treatments may
have contributed to the patient's hemolysis. The advanced
anemia in these three cases that precipitated their hospi-
talizations correlated well with their high homocysteine
levels on admission.
The role of homocysteine in increasing the risk of hemol-
ysis in vitamin B12 and folate deficiency has been demon-
Peripheral smear of case 2 demonstrated macrocytosis with anisopoikilocytosis and one hyper egm nted neutrophil/granul cyte with schistocytesFigur  2
Peripheral smear of case 2 demonstrated macrocytosis with 
anisopoikilocytosis and one hypersegmented neutrophil/
granulocyte with schistocytes.
Bone morrow of case 2 demonstrated macromegaloblastic erythropoiesisFigu e 3
Bone morrow of case 2 demonstrated macromegaloblastic 
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been well appreciated as a possible cause of hemolysis in
the clinical setting. We believe that the high homocysteine
levels in the above three cases may have played a role in
ensuing hemolysis in addition to intramedullary destruc-
tion of RBC as evidenced by the fact that both hemolysis
and pancytopenia as well as the hyperhomocysteinemia
were all corrected by cobalamin treatments. It is also evi-
dent that all the three cases reported here either had het-
erozygous or homozygous MTHFR gene mutations that
are known causes of hyperhomocysteinemia though the
level of hyperhomocysteinemia may differ between differ-
ent polymorphisms of MTHFR genes [6]. With the addi-
tional impact of vitamin B12 deficiency on the preexisting
hyperhomocysteinemia, hemolysis may occur in both
intravascular and intramedullary settings, resulting in a
drastic reduction of circulating red blood cell mass.
Other evidence implicating the role of homocysteine's
hemolytic effects is mainly observed in patients with
HELLP (Hemolysis-Elevated Liver Enzymes-Low Platelet)
syndrome. While the etiology of HELLP syndrome is not
clear, elevated homocysteine levels are often observed
among pre-eclamptic patients and have been considered
as a risk factor for hemolysis and endothelial damage with
ensuing microangiopathy is proposed as the pathophysi-
ologic mechanism of this disorder [7,8]. Other cases in
the literature included two young siblings who had a
hereditary disorder of cobalamin metabolism (Cbl-C
defect) presenting with proteinuria, hematuria, hyperten-
sion, and chronic hemolytic anemia with elevated levels
of homocysteine [9]. Both patients received renal biopsies
with the findings consistent with thrombotic microangio-
pathy. With the treatment of parenteral hydroxycobala-
min and folic acid, the homocysteine levels were reduced
significantly with a complete resolution of hemolysis and
hematuria [9]. The above two cases and ours suggest the
potential association between hyperhomocysteinemia
and hemolysis.
Homocysteine has been proposed as a hemolytic toxin
[4]. While the exact mechanism of homocysteine's hemo-
lytic effects is not clear, its pro-oxidant attributes have
been suggested as a cause [4]. A recent discovery of homo-
cysteine's effect on the down-regulation of cellular glu-
tathione peroxidase-1 activity implicated its role in
facilitating the accumulation of reactive oxygen species
[10], which may subsequently instigate the oxidative vul-
nerability of sulfhydryl groups of hemoglobin and thus
lead to hemoglobin precipitates within the RBC. How-
ever, such intracellular changes would not be expected to
lead to the microangiopathic changes in the blood smears
seen in our cases.
Another mechanism may be a consequence of the
endothelial damage resulting from high homocysteine
levels, with ensuing microangiopathy causing hemolysis.
Evidence suggesting that hyperhomocysteinemia is associ-
ated with thrombosis [11-14] and endothelial damage or
dysfunction [5,14] is abundant. In those reports, the pro-
oxidant effects of homocyteine were posited as the likely
cause of endothelial damage. Studies also suggested that
vitamin B12 deficiency may be associated with an
increased risk of thrombosis, possibly as a result of hyper-
homocysteinemia [14-16]. Furthermore, a recent study
demonstrated that endothelial dysfunction can be cor-
rected with vitamin B12 and folic acid treatments in
patients with both homozygous MTHFR C677T muta-
tions and vitamin B12 deficiency (with hyperhomo-
cysteinemia) [5]. While some patients with elevated
homocysteine levels do not have a complicating hemo-
lytic anemia, as in homocysteinuria and MTHFR gene
mutations, the microangiopathic changes in the periph-
eral blood smears in our cases may be explained by the
susceptibility of structurally defective megaloblastic eryth-
rocytes to endothelial damage caused by hyperhomo-
cysteinemia when compared to structurally normal
erythrocytes.
Andres et al. reported hematological findings in 201 con-
secutive patients with vitamin B12 deficiency [1]. Approx-
imately 10% of the patients had life threatening
hematological manifestations, including symptomatic
pancytopenia (5%), "pseudo" thrombotic microangiopa-
thy (2.5%), and hemolytic anemia (1.5%) [1]. A signifi-
cant proportion of these patients underwent invasive and
comprehensive diagnostic panels to rule out other causes
of such abnormalities. At times, these patients were misdi-
agnosed and treated with aggressive measures such as ster-
oids, polyvalent immunoglobulins, and plasmapheresis
[1]. It may be possible that the small percentage of cases
with evidence of peripheral blood hemolysis were those
with extreme elevations of homocysteine levels.
We report here three cases of severe hyperhomocysteine-
mia caused by vitamin B12 deficiency and MTHFR gene
mutations and hemolysis that completely resolved after
vitamin B12 therapy. Our cases illustrate the likely culprit
of extreme homocysteinemia in precipitating hemolysis
in patients with vitamin B12 deficiency and MTHFR gene
mutations. Severe hematological complications such as
hemolytic anemia and microangiopathy may be more
prevalent in patients who have coexisting MTHFR gene
mutations and vitamin B12 deficiency possibly related to
severely elevated homocysteine levels. To our knowledge,
there is no literature report on the association between
vitamin B12 deficiency and MTHFR gene mutations as a
possible cause of peripheral blood hemolysis. Based upon
our observations and the literature review, we are propos-Page 4 of 5
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ing a prospective study to examine the association
between vitamin B12 deficiency and MTHFR gene muta-
tions in relationship to the incidence and severity of
hyperhomocysteinemia, hemolytic anemia and microan-
giopathy.
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